PA-BOOMI
15.4.2024 15:01:27 CEST | Business Wire | Press release
Boomi™, the intelligent integration and automation leader, today announced findings from its Boomi Discovery Report, commissioned by 451 Research.1 The report, based on perspectives from 650 business and IT leaders across a broad range of industries, outlines how enterprises are using Generative AI (GenAI) to integrate systems and automate processes, and how this has helped their business operations as a result.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415795607/en/
Boomi Discovery Report Reveals More Than Half of Enterprises Invest in GenAI for Integration and Automation (Graphic: Business Wire)
Every business is grappling with growing digital fragmentation – from application sprawl and disconnect between departments, to rising costs and skills shortages. GenAI delivers the promise of more efficient and cost-effective operations and improved customer and employee experiences, but only for businesses that embrace it.
According to the Boomi Discovery Report, organizations are seeing GenAI’s immediate impact on integration. More than half of respondents (55%) said GenAI was very important for integrating data, applications, and processes. Moreover, the global drivers of AI adoption included increased productivity (which 44% of executives cited), increased sales and revenue growth (40%), and improved customer experience (39%).
However, respondents acknowledged the complexity that’s often associated with integration. Many times, integrating data and systems can bring challenges that prompt security and privacy concerns (42%), data quality and availability challenges (42%), and model training, accuracy, and reliability (31%). According to the report, 90% of respondents agree that GenAI has the potential to improve the speed and quality of the development and automation of data, application, and process integrations.
“The ability to seamlessly integrate and automate business processes has long been a top priority for many enterprises,” said Steve Lucas, CEO at Boomi. “As organizations scale and continue to navigate unforeseen business challenges, it will become more difficult to keep track of all the data, technology, and processes necessary to achieve business goals. Generative AI can be a powerful tool for today’s enterprises, streamlining valuable integration and automation practices and freeing IT teams to focus on innovation. Finding ways to leverage GenAI effectively is the next business prerogative. Boomi is not only helping get businesses ready for it, but also leading the GenAI charge in the integration and automation space."
Additional key findings from the report include:
- IT leaders have more trust in GenAI than business leaders: IT CxOs have a higher rate of trust – 82% either “completely” or “somewhat” trust the output of GenAI, versus 63% of business CxOs.
- Accuracy and consistency are major factors driving trust in GenAI: More than half of business leaders (57%) cited accuracy and quality of AI outputs as a factor in their trust of AI. Just under half (48%) cited consistency and reliability as an AI trust factor.
- Enterprise execs see tremendous value in GenAI: Leaders cited improved process accuracy and consistency (38%), cost reduction (38%), innovation and creativity (34%), streamlined operations (31%), optimized resources (28%), and enablement of competitive advantage (27%) as top potential benefits for leveraging GenAI.
- GenAI has widespread value for integrations: All respondents believe that virtually any type of integration would benefit from GenAI-assisted integration platforms.
“Integration and automation are the foundation upon which enterprises build business agility,” said Matt McLarty, CTO at Boomi. “However, integrating and automating systems isn’t always easy. This is why it pays off to have a unified approach for both. With a unified platform, powered by AI technology, enterprises can gain the advantages of comprehensive integration and automation while mitigating unwanted complexity.”
For more information on the 2024 Boomi Discovery Report, click here.
Additional Resources
- Learn more about the Boomi platform
- Follow Boomi on Twitter, LinkedIn, Facebook, and YouTube
About Boomi
Boomi powers the future of business with intelligent integration and automation. As a category-leading, global software as a service (SaaS) company, Boomi celebrates more than 20,000 global customers and a worldwide network of 800 partners. Organizations turn to Boomi’s award-winning platform to connect their applications, data, and people to accelerate digital transformation. For more information, visit boomi.com.
© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
Methodology
The findings presented in this report draw on a survey fielded in North America and Europe in Q4 2023. The survey targeted 650 business and IT decision-makers/influencers in companies ranging in size from under 100 to over 25,000 employees, and $2 million to over $10 billion in annual revenue. The study prioritized respondents with intimate knowledge of automation and integration technology across a broad range of diverse industries asking them about their perception of, and propensity to use, AI technologies of various types, but more specifically about their use of GenAI. The job descriptions of respondents were a mix of executives ranging from Analyst/Manager grade to C-level Executives. This report also draws on contextual knowledge of additional research conducted by S&P Global Market Intelligence.
|
|
1Source: The Impact of AI on Enterprise Integration and Automation, 451 Research, a part of S&P Global Market Intelligence and Boomi, 2024. All Rights Reserved |
|
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240415795607/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
